| Q39136403 | 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. |
| Q45718710 | 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization |
| Q46863819 | 4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells |
| Q91707881 | A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer |
| Q28550391 | A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces |
| Q92800244 | A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three |
| Q40230470 | A STING-activating nanovaccine for cancer immunotherapy |
| Q52617409 | A Targeted LC-MS Strategy for Low-Abundant HLA Class-I-Presented Peptide Detection Identifies Novel Human Papillomavirus T-Cell Epitopes. |
| Q90613217 | A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer |
| Q52579555 | A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. |
| Q95319497 | A guide to cancer immunotherapy: from T cell basic science to clinical practice |
| Q47157821 | A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer. |
| Q90648467 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
| Q92884989 | Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade |
| Q90479566 | Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research |
| Q39045586 | Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities |
| Q46205951 | Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. |
| Q47263239 | Alteration of the tumor stroma using a consensus DNA vaccine targeting Fibroblast Activation Protein (FAP) synergizes with anti-tumor vaccine therapy in mice |
| Q91666603 | Alternative tumour-specific antigens |
| Q90316720 | An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses |
| Q38739446 | An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. |
| Q36604367 | Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry |
| Q58773669 | Analysis of the Minor Histocompatibility Antigen Landscape Based on the 1000 Genomes Project |
| Q26774312 | Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches |
| Q75719938 | Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells |
| Q64070843 | Antigen Targets for the Development of Immunotherapies in Leukemia |
| Q46398502 | Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. |
| Q88664225 | Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials |
| Q59092145 | Antitumour immunity gets a boost |
| Q30277192 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial |
| Q64108217 | Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity |
| Q90326633 | Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer |
| Q56894565 | Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices |
| Q47565901 | Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity |
| Q39032610 | Building proteomic tool boxes to monitor MHC class I and class II peptides |
| Q48185876 | CD4 and CD8 T lymphocyte interplay in controlling tumor growth |
| Q92480211 | CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response |
| Q47122613 | CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy |
| Q47760070 | Cancer Immunotherapy Targeted Glypican-3 or Neoantigens. |
| Q38825771 | Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells |
| Q92538386 | Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display |
| Q38600417 | Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations. |
| Q92310063 | Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors |
| Q29615679 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer |
| Q36889067 | Cancer immunotherapy targeting neoantigens |
| Q39451757 | Cancer immunotherapy: moving forward with peptide T cell vaccines |
| Q60933076 | Cancer research in the era of immunogenomics |
| Q26752491 | Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer |
| Q36110794 | Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. |
| Q37741534 | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. |
| Q33806351 | Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators |
| Q92095247 | Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics |
| Q90254063 | Challenges towards the realization of individualized cancer vaccines |
| Q41701367 | Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells |
| Q48225574 | Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy. |
| Q62002185 | Checkpoint parley |
| Q62002191 | Checkpoint parley |
| Q95832579 | Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer |
| Q33361064 | Citizens unite for computational immunology! |
| Q35674821 | Classifying Cancers Based on T-cell Infiltration and PD-L1. |
| Q28084766 | Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer |
| Q64096309 | Clinical potential of mass spectrometry-based proteogenomics |
| Q38669465 | Clinical relevance of host immunity in breast cancer: from TILs to the clinic |
| Q39092611 | Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia |
| Q52603627 | Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. |
| Q48050678 | Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. |
| Q64122192 | Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma |
| Q64968387 | Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. |
| Q99635480 | Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer |
| Q90711814 | Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability |
| Q37193493 | Comprehensive analyses of tumor immunity: implications for cancer immunotherapy |
| Q49237244 | Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial |
| Q89965571 | Computational Prediction and Validation of Tumor-Associated Neoantigens |
| Q35872350 | Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma |
| Q90419584 | Current Perspectives in Cancer Immunotherapy |
| Q38953021 | Current tools for predicting cancer-specific T cell immunity |
| Q39384263 | DNA Damage and Repair Biomarkers of Immunotherapy Response |
| Q47113174 | DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. |
| Q38795937 | De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. |
| Q38612613 | Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. |
| Q90580775 | Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification |
| Q39243064 | Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. |
| Q37730767 | Designer vaccine nanodiscs for personalized cancer immunotherapy |
| Q64268794 | Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma |
| Q91782530 | Determinants for Neoantigen Identification |
| Q57201489 | Determining T-cell specificity to understand and treat disease |
| Q92221483 | Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9 |
| Q99406539 | Dexamethasone premedication suppresses vaccine-induced immune responses against cancer |
| Q27853176 | Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers |
| Q47716902 | Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma |
| Q42143897 | Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry |
| Q38347244 | Discovering protective CD8 T cell epitopes--no single immunologic property predicts it! |
| Q64258056 | Disruption of sialic acid metabolism drives tumor growth by augmenting CD8 T cell apoptosis |
| Q66678841 | Divergent Peptide Presentations of HLA-A30 Alleles Revealed by Structures With Pathogen Peptides |
| Q39380597 | Do checkpoint inhibitors rely on gut microbiota to fight cancer? |
| Q42378431 | Effective antitumor peptide vaccines can induce severe autoimmune pathology. |
| Q38831440 | Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. |
| Q92912425 | Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer |
| Q39094764 | Elements of cancer immunity and the cancer-immune set point |
| Q55044963 | Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. |
| Q51275962 | Emerging biomarkers for PD-1 pathway cancer therapy. |
| Q38796338 | Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers |
| Q36340870 | Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer |
| Q46217247 | Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach |
| Q38660577 | Engineered Materials for Cancer Immunotherapy. |
| Q92893753 | Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy |
| Q28085563 | Engineering New Approaches to Cancer Vaccines |
| Q92578264 | Engineering patient-specific cancer immunotherapies |
| Q90213090 | Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles |
| Q37370230 | Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy |
| Q89574430 | Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy |
| Q42573824 | Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation |
| Q37554718 | Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses |
| Q64108588 | Errors in translational decoding: tRNA wobbling or misincorporation? |
| Q50317337 | Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer |
| Q47318878 | Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients |
| Q99418959 | Evolutionary dynamics of neoantigens in growing tumors |
| Q38553010 | Evolving synergistic combinations of targeted immunotherapies to combat cancer. |
| Q47797670 | Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy |
| Q28088304 | From mice to humans: developments in cancer immunoediting |
| Q64884539 | Functional genomics: paving the way for more successful cancer immunotherapy. |
| Q47139891 | Functional profiling of microtumors to identify cancer associated fibroblast-derived drug targets |
| Q38607706 | Gene therapy returns to centre stage |
| Q35718060 | Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes |
| Q38362051 | Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies |
| Q91871630 | Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications |
| Q38971262 | Genomic Approaches to Understanding Response and Resistance to Immunotherapy |
| Q37319470 | Genomic correlates of response to CTLA-4 blockade in metastatic melanoma |
| Q92179996 | Genomic correlates of response to immune checkpoint blockade |
| Q91956657 | Genomics-Guided Immunotherapy for Precision Medicine in Cancer |
| Q52666692 | Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. |
| Q38516823 | Glioblastoma antigen discovery--foundations for immunotherapy. |
| Q41906355 | Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames |
| Q92988727 | Glycan-Modified Apoptotic Melanoma-Derived Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination |
| Q47835567 | HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses |
| Q90322274 | Harnessing neoantigen specific CD4 T cells for cancer immunotherapy |
| Q39175714 | Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer |
| Q28066792 | High-content molecular profiling of T-cell therapy in oncology |
| Q94236150 | Highlights from the Literature |
| Q38390185 | Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. |
| Q89928899 | IL-27p28 Production by XCR1+ Dendritic Cells and Monocytes Effectively Predicts Adjuvant-Elicited CD8+ T Cell Responses |
| Q51710292 | IMMUNOTHERAPY. Outsourcing the immune response to cancer. |
| Q47133741 | Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients |
| Q38968213 | Identification of Small Novel Coding Sequences, a Proteogenomics Endeavor |
| Q33788685 | Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors |
| Q37477282 | Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases. |
| Q62050532 | Identifying neoantigens for use in immunotherapy |
| Q35662996 | IgRepertoireConstructor: a novel algorithm for antibody repertoire construction and immunoproteogenomics analysis |
| Q36024656 | Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). |
| Q47101602 | Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology. |
| Q26781794 | Immune responses to human cancer stem-like cells/cancer-initiating cells |
| Q58926297 | Immune system offers clues to cancer treatment |
| Q39057617 | Immune targets and neoantigens for cancer immunotherapy and precision medicine |
| Q48193651 | Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance |
| Q39165919 | Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models |
| Q64088491 | Immunogenicity of Tumor Initiating Stem Cells: Potential Applications in Novel Anticancer Therapy |
| Q38611895 | Immunological landscape and immunotherapy of hepatocellular carcinoma |
| Q49483662 | Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens |
| Q41497500 | Immunoproteasomes edit tumors, which then escapes immune recognition |
| Q92811129 | Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges |
| Q26776184 | Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies |
| Q36224057 | Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy |
| Q36222122 | Immunotherapy in the Precision Medicine Era: Melanoma and Beyond |
| Q52992331 | Immunotherapy: personalizing tumour vaccines. |
| Q49835132 | Improving Cancer Immunotherapies through Empirical Neoantigen Selection |
| Q26766267 | Improving the clinical impact of biomaterials in cancer immunotherapy |
| Q92126199 | Induction of neoantigen-reactive T cells from healthy donors |
| Q26769744 | Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity |
| Q26782583 | Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine |
| Q47146257 | Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy |
| Q40099497 | Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells |
| Q101166708 | Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells |
| Q47279363 | Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name |
| Q49645497 | Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Targeting the Right Antigens in the Right Patients |
| Q36165605 | Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes |
| Q36676636 | LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations |
| Q90066859 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment |
| Q37304964 | Leveraging premalignant biology for immune-based cancer prevention |
| Q50454256 | Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. |
| Q36021163 | Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. |
| Q37452154 | MHC class I-associated peptides derive from selective regions of the human genome |
| Q38844572 | MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics |
| Q91671018 | Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors |
| Q51068702 | Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. |
| Q57178228 | Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry |
| Q89944200 | Mass Spectrometry-Based Identification of MHC-Associated Peptides |
| Q92899524 | Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection |
| Q34522172 | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy |
| Q36429062 | Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth |
| Q27853331 | Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. |
| Q38901338 | Metastatic melanoma and immunotherapy |
| Q47666252 | Mice expressing human ERAP1 variants associated with ankylosing spondylitis have altered T-cell repertoires and NK cell functions, as well as increased in utero and perinatal mortality. |
| Q36583731 | Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. |
| Q47292249 | Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. |
| Q37295260 | Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections |
| Q92034605 | Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy |
| Q64079285 | Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma |
| Q26769044 | Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination |
| Q42777878 | Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer |
| Q64084665 | Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma |
| Q90021348 | NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines |
| Q50048512 | Nanocage-Therapeutics Prevailing Phagocytosis and Immunogenic Cell Death Awakens Immunity against Cancer |
| Q88716389 | Nature of tumour rejection antigens in ovarian cancer |
| Q47221163 | Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy? |
| Q57177418 | Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy |
| Q61814408 | Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome |
| Q92827446 | Neoantigen vaccine: an emerging tumor immunotherapy |
| Q97644519 | Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal |
| Q26738693 | Neoantigen-based cancer immunotherapy |
| Q47320909 | Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy |
| Q89965697 | Neoantigens in Hematologic Malignancies |
| Q92539066 | Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy? |
| Q34470074 | Neoantigens in cancer immunotherapy. |
| Q39183391 | Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. |
| Q26784047 | Neoepitopes of Cancers: Looking Back, Looking Ahead |
| Q38397279 | New clinical advances in immunotherapy for the treatment of solid tumours. |
| Q37578747 | New discoveries in the molecular landscape of bladder cancer. |
| Q64899889 | New epitopes in ovalbumin provide insights for cancer neoepitopes. |
| Q58791982 | Next Generation Cancer Vaccines-Make It Personal! |
| Q38754313 | Next-Generation Sequencing to Guide Treatment of Advanced Melanoma |
| Q89456690 | Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer |
| Q26801946 | Next-generation sequencing to guide cancer therapy |
| Q38541767 | Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy |
| Q90811860 | Nouvelles approches vaccinales en cancérologie |
| Q38646138 | Novel Treatments in Development for Melanoma. |
| Q90324391 | Novel frontiers in detecting cancer metastasis |
| Q26770780 | Novel technologies and emerging biomarkers for personalized cancer immunotherapy |
| Q47660956 | Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction |
| Q39230055 | Oncolytic Virotherapy: A Contest between Apples and Oranges |
| Q47162004 | Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses |
| Q89097115 | Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models |
| Q26738680 | Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines |
| Q26829885 | Overcoming T cell exhaustion in infection and cancer |
| Q38578968 | Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer |
| Q28262647 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency |
| Q27313748 | PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model |
| Q28084090 | PD-L1 and Survival in Solid Tumors: A Meta-Analysis |
| Q47105638 | PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors |
| Q42289790 | PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy |
| Q28260529 | POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer |
| Q33785947 | PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity |
| Q48156858 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy |
| Q36225280 | Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine Vectors |
| Q39035351 | Peptide vaccines in cancer-old concept revisited |
| Q92610736 | Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens |
| Q93039767 | Personalized Neo-Epitope Vaccines for Cancer Treatment |
| Q50906889 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. |
| Q64988012 | Personalized cancer neoantigen vaccines come of age. |
| Q49956120 | Personalized cancer vaccines: Targeting the cancer mutanome |
| Q96128333 | Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives |
| Q91744190 | Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models |
| Q39004582 | Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. |
| Q64245690 | Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth |
| Q52589523 | Population-level distribution and putative immunogenicity of cancer neoepitopes. |
| Q90304460 | Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy |
| Q50055098 | Potentiating prostate cancer immunotherapy with oncolytic viruses |
| Q89457621 | Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome |
| Q49668436 | Preclinical and clinical development of neoantigen vaccines |
| Q54255264 | Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. |
| Q90704104 | Predicting HLA class II antigen presentation through integrated deep learning |
| Q58129532 | Predicting T cell recognition of MHC class I restricted neoepitopes |
| Q38647855 | Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells |
| Q31148562 | Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing. |
| Q98771735 | Progress in Neoantigen Targeted Cancer Immunotherapies |
| Q38758988 | Prospect and progress of personalized peptide vaccinations for advanced cancers |
| Q48244442 | Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers. |
| Q38670152 | Proteogenomics from a bioinformatics angle: A growing field. |
| Q38547265 | Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens |
| Q36464016 | Proteomic contributions to our understanding of vaccine and immune responses |
| Q50070316 | Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system |
| Q92172461 | Quantifying immune-based counterselection of somatic mutations |
| Q64056269 | RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade |
| Q58698657 | RNA editing derived epitopes function as cancer antigens to elicit immune responses |
| Q39017268 | Radiotherapy and immunotherapy: a beneficial liaison? |
| Q26738443 | Radiotherapy combination opportunities leveraging immunity for the next oncology practice |
| Q40788906 | Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination |
| Q38730141 | Rare cancers: a sea of opportunity |
| Q92859230 | Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation |
| Q60948122 | Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens |
| Q28067217 | Recent advances in understanding antitumor immunity |
| Q90426278 | Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment |
| Q90639891 | Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer |
| Q89538412 | Research Progress Evaluating the Function and Mechanism of Anti-Tumor Peptides |
| Q38731119 | STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. |
| Q38704265 | Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen |
| Q39438407 | Secreted tumor antigens - immune biomarkers for diagnosis and therapy. |
| Q96137394 | Self-healing microcapsules synergetically modulate immunization microenvironments for potent cancer vaccination |
| Q93101149 | Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood |
| Q55008935 | Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. |
| Q40104793 | Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines |
| Q36159205 | Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling |
| Q41325257 | Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency |
| Q88764273 | Structural basis for ADP-dependent glucokinase inhibition by 8-bromo-substituted adenosine nucleotide |
| Q98513865 | Structural dissimilarity from self drives neoepitope escape from immune tolerance |
| Q90290722 | Structure Based Prediction of Neoantigen Immunogenicity |
| Q55046482 | Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. |
| Q47145915 | Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells |
| Q41035371 | Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses |
| Q58587953 | Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes |
| Q95310618 | T Cell Receptor Engineered Lymphocytes for Cancer Therapy |
| Q48247566 | T cell receptor β-chain repertoire analysis reveals the association between neoantigens and tumour-infiltrating lymphocytes in multifocal papillary thyroid carcinoma. |
| Q50861629 | T-Cell Epitope Discovery for Therapeutic Cancer Vaccines. |
| Q90176790 | T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies |
| Q39160959 | TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy |
| Q30668579 | TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst |
| Q35377746 | TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. |
| Q27316403 | TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection |
| Q38855909 | TIL 2.0: More effective and predictive T-cell products by enrichment for defined antigen specificities |
| Q50116964 | TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer |
| Q50130464 | Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications. |
| Q38366556 | Targeting cancer-specific mutations by T cell receptor gene therapy |
| Q36618620 | Targeting human melanoma neoantigens by T cell receptor gene therapy |
| Q47433391 | Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. |
| Q37223669 | Targeting neoantigens for cancer immunotherapy |
| Q39149196 | Targeting neoantigens to augment antitumour immunity |
| Q34677333 | Targeting of cancer neoantigens with donor-derived T cell receptor repertoires |
| Q36316627 | Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. |
| Q91799734 | The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine |
| Q38768283 | The Damaging Effect of Passenger Mutations on Cancer Progression |
| Q91711253 | The Graft-Versus-Leukemia Effect in AML |
| Q91343733 | The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases |
| Q38807692 | The Human Vaccines Project: A roadmap for cancer vaccine development |
| Q41189810 | The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors |
| Q38753386 | The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer |
| Q42204343 | The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. |
| Q47678849 | The diverse functions of the PD1 inhibitory pathway |
| Q91520697 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy |
| Q38829558 | The future of immunotherapy for sarcoma |
| Q48461416 | The immunocheckpoints in modern oncology: the next 15 years. |
| Q97067351 | The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis |
| Q102211076 | The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses |
| Q55001351 | The perfect personalized cancer therapy: cancer vaccines against neoantigens. |
| Q34528638 | The present status and future prospects of peptide-based cancer vaccines |
| Q39427595 | The role of MHC genes in contagious cancer: the story of Tasmanian devils |
| Q47190955 | The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction |
| Q90481320 | The role of proteomics in the age of immunotherapies |
| Q58924840 | The swinging pendulum of cancer immunotherapy personalization |
| Q39828989 | The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors |
| Q40728648 | Therapeutic Cancer Vaccines |
| Q50988785 | Therapeutic cancer vaccines. |
| Q90339758 | Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells |
| Q38650013 | Tools to define the melanoma-associated immunopeptidome. |
| Q96641056 | Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire |
| Q47789519 | Towards personalized, tumour-specific, therapeutic vaccines for cancer. |
| Q37660771 | Transient Treg depletion enhances therapeutic anti-cancer vaccination. |
| Q38878056 | Translational value of mouse models in oncology drug development |
| Q56893452 | Trial watch: DNA-based vaccines for oncological indications |
| Q56594845 | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics |
| Q37422116 | Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures |
| Q89525448 | Tumor immune microenvironment in head and neck cancers |
| Q92579646 | Tumor mutation burden: from comprehensive mutational screening to the clinic |
| Q91895975 | Tumor mutational burden quantification from targeted gene panels: major advancements and challenges |
| Q28082704 | Tumor neoantigens: building a framework for personalized cancer immunotherapy |
| Q93157712 | Tumor neoantigens: from basic research to clinical applications |
| Q92757018 | Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity |
| Q37660698 | Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice |
| Q58927160 | Tumour mutations harnessed to build cancer vaccine |
| Q38787035 | Unmasking targets of antitumor immunity via high-throughput antigen profiling |
| Q30391717 | Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions |
| Q57050167 | Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules |
| Q50222492 | Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells |
| Q39791206 | Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. |
| Q37035972 | Viral infection causes a shift in the self peptide repertoire presented by human MHC class I molecules |
| Q89850600 | dbPepNeo: a manually curated database for human tumor neoantigen peptides |
| Q39013357 | mRNA Cancer Vaccines |
| Q37202382 | sNebula, a network-based algorithm to predict binding between human leukocyte antigens and peptides |
| Q26861133 | αβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy |